Compass Therapeutics (CMPX) is a Boston-based, clinical-stage oncology biopharma developing proprietary monoclonal and bispecific antibodies aimed at reprogramming the tumor microenvironment—specifically the intersection of angiogenesis, immune suppression, and tumor growth. The company is pre-commercial and does not generate recurring product revenue; funding is primarily from capital raises with modest interest income and occasional licensing-related revenue. FY2025 reflected an intensifying late-stage posture: net loss widened to ~$66.5M as R&D and manufacturing spend increased to support pivotal development, while the balance sheet strengthened materially to ~$209M in cash/marketable securities, which management expects to fund operations into 2028. The pipeline is led by tovecimig (CTX-009), a DLL4 x VEGF-A bispecific in Phase 2/3 for second-line biliary tract cancer, with a statistically significant ORR advantage versus paclitaxel (17.1% vs 5.3%)—positioning the company at a pivotal inflection. Other programs provide optionality: CTX-8371 (PD-1 x PD-L1) aims to unlock responses in checkpoint-refractory patients via a differentiated mechanism involving PD-1 receptor cleavage; CTX-10726 (PD-1 x VEGF-A) is entering Phase 1 with claims of superior preclinical activity versus ivonescimab-like comparators; and CTX-471 is a differentiated CD137 agonist designed to maximize immune activation while reducing hepatotoxicity risk. The investment case is dominated by the April 2026 OS/PFS readout for tovecimig, which will determine regulatory trajectory and commercial feasibility.

Compass Therapeutics, Inc. (CMPX) Investment Analysis:

1. Executive Summary

Compass Therapeutics, Inc. (Nasdaq: CMPX) is a clinical-stage oncology biopharmaceutical company headquartered in Boston, Massachusetts, focused on the development of proprietary antibody-based therapeutics.[1, 2] The entity distinguishes itself within the competitive biotechnology landscape by concentrating on the intricate relationship between angiogenesis, the immune system, and tumor growth.[3, 4] The primary mission of the organization centers on modulating the tumor microenvironment through high-affinity bispecific and monoclonal antibodies designed to overcome the limitations of current standards of care in solid tumors and hematological malignancies.[2, 5, 6]

As a clinical-stage company, Compass Therapeutics does not currently generate revenue from product sales.[1, 7] The financial model currently relies on the intermittent recognition of licensing revenue and, more significantly, the periodic raising of capital through the public equity markets to fund intensive research and development (R&D) activities.[1, 8, 9] In the fiscal year 2025, the company reported a net loss of $66.5 million, reflecting a strategic increase in expenditures related to the manufacturing of its lead assets and the execution of late-stage clinical trials.[1, 6, 10] Despite the lack of recurring revenue, the company maintains a robust financial position, ending 2025 with $209 million in cash and marketable securities, which management projects will fund operations into 2028.[1, 6, 7]

The core product portfolio comprises four distinct clinical candidates, each targeting critical pathways in oncology. Tovecimig (CTX-009) is the most advanced asset, a bispecific antibody targeting Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A).[11, 12] This candidate is currently being evaluated in a Phase 2/3 study for second-line biliary tract cancer (BTC) and has demonstrated a statistically significant improvement in overall response rates compared to chemotherapy alone.[13, 14] Supporting this lead program is CTX-8371, a next-generation bispecific targeting PD-1 and PD-L1, which has shown deep clinical responses in patients refractory to previous checkpoint inhibitors.[15, 16, 17] The pipeline also includes CTX-10726, a PD-1 x VEGF-A bispecific entering Phase 1 trials, and CTX-471, a CD137 agonist designed with a unique epitope to maximize immune activation while minimizing the hepatotoxicity that has plagued earlier generation drugs in this class.[13, 18, 19]

The primary customer types for Compass Therapeutics, following successful regulatory approval, are healthcare providers, including oncology clinics, specialized cancer centers, and hospitals.[2, 20] The company’s most important end markets include the approximately 25,000 patients diagnosed annually in the United States with biliary tract cancer, as well as the broader, multibillion-dollar markets for colorectal cancer (CRC), non-small cell lung cancer (NSCLC), and triple-negative breast cancer (TNBC).[21, 22] Customers—both physicians and patients—are anticipated to choose Compass Therapeutics’ products over existing alternatives due to superior efficacy in refractory settings, differentiated safety profiles, and the potential for a more durable anti-tumor response afforded by the company's multispecific antibody formats.[2, 12, 23]

The strategic importance of Compass Therapeutics lies in its ability to combine the blockade of angiogenesis with the activation of the immune system within a single therapeutic molecule.[3, 23] This dual-action approach aims to treat the "unmet needs" of patients who have progressed after prior therapies, positioning the company as a high-value innovator in a specialized segment of the oncology market.[2, 12, 24]

PIVOTAL CLINICAL INFLECTION

2. Business Drivers & Strategic Overview

The economic and strategic engine of Compass Therapeutics is its proprietary drug discovery and development platform, which enables the rapid identification and optimization of multispecific antibodies.[5, 23] The company’s strategy is built upon the premise that simultaneously targeting multiple biological pathways is required to achieve an effective anti-tumor response in most solid tumors.[3, 6]

2.1 Core Product Portfolio and Mechanism of Action

To understand what is actually being sold—or what will be sold upon commercialization—it is necessary to examine the molecular specificity and clinical positioning of the lead assets.[2, 13]

Candidate	Targets	Primary Indication	Phase	Key Differentiator
Tovecimig (CTX-009)	DLL4 x VEGF-A	Biliary Tract Cancer (2L)	2/3	Statistically significant ORR vs Paclitaxel [13]
CTX-8371	PD-1 x PD-L1	NSCLC, TNBC, HL	1	Unique PD-1 cleavage mechanism [25]
CTX-10726	PD-1 x VEGF-A	Advanced Solid Tumors	1	Superior tumor control vs Ivonescimab in models [19]
CTX-471	CD137 (4-1BB)	NCAM+ Tumors	2	Potent activation without hepatotoxicity [11]

Tovecimig is an investigational bispecific antibody that blocks both the DLL4 and VEGF-A signaling pathways, which are critical to the formation of tumor-supporting blood vessels.[14, 26] Traditional VEGF-targeted therapies, such as bevacizumab, often fail when tumors activate compensatory pathways, such as the Notch signaling pathway mediated by DLL4.[4, 11] By simultaneously inhibiting both, tovecimig prevents this escape mechanism, leading to more robust anti-tumor activity.[11, 14] In clinical trials, this has translated into a 17.1% overall response rate in second-line BTC, compared to only 5.3% for standard paclitaxel chemotherapy.[12, 13, 14]

CTX-8371 represents a fundamental shift in checkpoint inhibition.[25] While standard therapies block either the PD-1 receptor or the PD-L1 ligand, CTX-8371 engages both.[11, 17] Its unique mechanism involves the actual cleavage of the PD-1 receptor from the surface of T cells, which potentially offers a more profound and lasting release of immune suppression than simple binding.[25, 27] This mechanism has shown early evidence of "rescuing" patients who have already failed prior PD-1/PD-L1 therapies, a high-value and growing patient population.[16, 28, 29]

CTX-10726 is a tetravalent bispecific antibody designed to deliver synergistic VEGF-A blockade and PD-1 inhibition.[19, 30] This asset is being positioned to compete in the highly lucrative PD-1/VEGF market, currently defined by candidates like ivonescimab.[16, 31] Compass reports that CTX-10726 has demonstrated superior tumor control and more potent PD-1 inhibition than ivonescimab in various xenograft and syngeneic mouse models, providing a strong rationale for its first-in-human testing in 2026.[1, 15, 16, 19]

2.2 Moat Analysis and Competitive Advantages

The competitive advantage of Compass Therapeutics is rooted in its intellectual property, manufacturing capabilities, and specialized scientific focus.[2, 3, 23]

• Intellectual Property (IP) and Regulatory Exclusivity: The company maintains proprietary rights to its antibody sequences and formats.[1, 2] Regulatory status acts as a secondary moat; for instance, the FDA has granted tovecimig Orphan Drug Designation and Fast Track Designation in biliary tract cancer.[2, 12] These designations provide up to seven years of market exclusivity upon approval and an accelerated pathway for regulatory interactions.[2, 12]
• StitchMabs™ and Discovery Platforms: The StitchMabs™ platform enables the rapid creation and empirical screening of bispecific antibodies in large matrix experiments.[23] This allows the company to identify synergistic combinations that might not be predicted by biology alone, effectively creating a discovery "engine" that can generate multiple candidates from a single common light chain sequence.[23]
• Manufacturing Yield and Cost Advantage: A significant barrier in bispecific antibody development is the low yield and manufacturing complexity of complex proteins.[23] Compass utilizes a common light chain-focused discovery process, which ensures that its bispecific candidates behave like traditional monoclonal antibodies in expression and purification.[23] The company has already achieved "commercially viable yields" for CTX-10726, a critical advantage for maintaining margins in a competitive oncology market.[16, 28]
• Scientific Niche (The CD137 "Holy Grail"): The industry has long sought a CD137 agonist that activates T cells without destroying the liver.[11] By identifying a unique epitope that provides potent co-stimulation with optimized affinity, Compass may have solved a problem that has caused numerous high-profile clinical failures at larger firms.[11, 13] This "first-in-class" potential creates a powerful brand and clinical moat.[2]

2.3 TAM and Market Opportunity Analysis

The market opportunity for Compass Therapeutics is both specialized and expansive.[2, 10]

• Biliary Tract Cancer (BTC): The global BTC market is estimated at approximately $0.87 billion to $1.1 billion currently and is expected to grow to over $3.89 billion by 2030.[22, 32, 33, 34] In the U.S., about 25,000 patients are diagnosed annually.[21] With few approved options in the second-line setting, an approved tovecimig would likely capture a dominant market share.[12, 21, 24]
• Refractory Colorectal Cancer (CRC): Approximately 50-60% of metastatic CRC patients are treated in the third-line or later.[29] Standard therapies in this setting offer response rates of only 1-1.5%.[29] Tovecimig’s observed 5% response rate in heavily pre-treated populations, many of whom have failed two or more prior VEGF treatments, suggests a significant opportunity in a market where standard drugs like bevacizumab are widely used but eventually fail.[29]
• Angiogenesis Inhibitor Market: The broader VEGF inhibitor market was valued at $8.42 billion in 2025 and is projected to reach $15.67 billion by 2034.[35] By entering this market with bispecifics that target dual pathways (VEGF/DLL4 or VEGF/PD-1), Compass aims to disrupt the dominance of existing monoclonals.[16, 35]

2.4 Competitive Landscape

Compass Therapeutics is positioned as a sophisticated challenger to both large-cap pharmaceutical companies and high-growth clinical-stage peers.[31, 33, 36]

• Large Pharmaceutical Entities: Companies like AstraZeneca (rilvegostomig), Merck (pembrolizumab/lenvatinib), and Roche (bevacizumab) are active in Compass’s target indications.[22, 33, 35, 37] AstraZeneca's rilvegostomig (PD-1/TIGIT) is a notable competitor in BTC, though its mechanism targets different immune checkpoints than tovecimig.[22, 37]
• Emerging Biotechs: Summit Therapeutics (SMMT) is the most direct competitor in the PD-1/VEGF space with ivonescimab.[16, 31] Summit’s shares have shown significant momentum after positive Phase III data in China, illustrating the high market value placed on effective PD-1/VEGF bispecifics.[31] Compass is strategically positioned as a "fast follower" with CTX-10726, claiming superior preclinical potency that could translate into better outcomes for the non-responders to existing PD-1 therapies.[16, 19]
• Market Trajectory: Compass appears to be gaining ground strategically.[1, 29, 38] The company successfully met its primary endpoint in the Phase 2/3 COMPANION-002 trial at a time when other angiogenesis-focused biotechs have struggled with toxicity and efficacy hurdles.[12, 13, 14] The recruitment of high-profile commercial and clinical leadership, including Chief Commercial Officer Arjun Prasad and Chief Medical Officer Cyndi Sirard, signals a company preparing for a successful transition from a research entity to a commercial enterprise.[1, 3, 6]

SCIENTIFIC DIFFERENTIATION ENGINE

3. Financial Performance & Valuation

Analysis of Compass Therapeutics' financials reveals a company in the "high-burn, high-potential" phase typical of clinical-stage biotechnology firms, but with a cash runway that is uncharacteristically long for the sector.[1, 2, 7]

3.1 Historical Performance (FY 2025)

The 2025 fiscal year was characterized by a widening net loss as the company aggressively moved tovecimig and CTX-10726 toward key milestones.[1, 8]

Metric (in thousands, except EPS)	2025 (Actual)	2024 (Actual)	Change (%)
Total Revenue	$0	$850	-100% [1, 8]
R&D Expense	$55,969	$42,342	+32% [1, 8]
G&A Expense	$16,870	$15,133	+11% [1, 8]
Operating Loss	($72,839)	($56,625)	+29% [1, 8]
Other Income (Interest)	$6,350	$7,250	-12% [1, 8]
Net Loss	($66,489)	($49,375)	+35% [1, 8]
Net Loss per Share (EPS)	($0.42)	($0.36)	+17% [1, 8]

The R&D increase of $13.7 million was primarily attributable to $7.7 million in manufacturing expenses for tovecimig and $5.9 million for CTX-10726.[1, 6] This demonstrates that the company is no longer just "discovering" but is actively building the supply chain necessary for pivotal data and commercial launch.[7, 16]

3.2 Balance Sheet and Liquidity

As of December 31, 2025, the company had $209 million in cash and marketable securities.[1, 6] This represents a significant increase from the $127 million held at the end of 2024.[8, 38] This liquidity boost was driven by a highly successful $129 million net proceeds underwritten public offering in mid-2025, which was upsized and oversubscribed, indicating strong institutional demand.[1, 18, 21]

With a 2025 net cash used in operating activities of $49 million, the current $209 million balance suggests a cash runway extending through 2027 and into 2028.[1, 6, 7, 10] This is a critical valuation driver, as it de-risks the company against near-term capital market volatility while it awaits transformational clinical readouts.[20, 39, 40]

3.3 Financial Assumptions and Valuation Drivers

Valuation for CMPX is not currently derived from earnings multiples but from the discounted probability-weighted value of its lead programs.[10, 40, 41]

• 5-Year Sales Growth: Analysts project revenue to begin in 2026/2027 following the potential tovecimig BLA filing and approval.[18, 21, 41] Consensus estimates for 2027 revenue average around $189 million, scaling sharply to $851 million by 2030 and potentially exceeding $1.5 billion by 2032 as the company expands into CRC and NSCLC.[41] This implies an exponential growth curve once the "pre-revenue" hurdle is cleared.[2, 41, 42]
• Operating Margins: While currently negative, biotech peers typically achieve 70-85% gross margins on proprietary antibodies once scaled.[35, 41] The key driver for Compass will be controlling G&A during the commercial rollout, where expenses are expected to rise as the company builds a specialty sales force for oncology centers.[1, 7, 10]
• Cost of Capital: As a growth asset, the company’s valuation is sensitive to interest rates.[2, 9] The company’s $209 million cash cushion allows it to earn significant interest income—$6.35 million in 2025—which partially offsets the R&D burn.[7, 8]

3.4 Connection to Core Business Model

The company's valuation is intrinsically tied to the "pivotal win" in the COMPANION-002 study.[13, 43] The market capitalization has recently fluctuated between $470 million and nearly $1 billion as investors react to pipeline progress.[2, 20, 38, 40] Analysts currently maintain an average price target of $13.77 to $15.50, representing an upside of over 150% from current trading levels.[41, 42, 44] This target price is essentially a bet that the tovecimig survival data (PFS/OS) due in April 2026 will support a BLA filing, turning a "clinical idea" into a "commercial reality".[6, 12, 43]

FUNDED FOR BREAKTHROUGH

4. Risk Assessment & Macroeconomic Considerations

The investment thesis for Compass Therapeutics is categorized as high-risk, high-reward, with several layers of execution and structural risk.[2, 13, 45]

4.1 Company-Specific Execution Risks

The single most significant short-term risk is the outcome of the overall survival (OS) and progression-free survival (PFS) analysis from the COMPANION-002 trial.[8, 12, 43] While the organization met the primary endpoint of ORR (17.1%), the secondary endpoints are what typically drive regulatory approval and commercial adoption in BTC.[13, 43] Management has noted that mortality in the trial has been "lower than originally projected," which they interpret as a signal that tovecimig is improving survival.[12, 16, 28] However, there is a risk that this lower mortality is a result of baseline patient characteristics across both arms, or that the p-value for survival fails to reach statistical significance.[43, 45] Failure to show a survival benefit would severely damage the long-term thesis and likely lead to a significant downward revision in the stock price.[45]

4.2 Competitive Risks

The oncology space, particularly for VEGF and PD-1 inhibitors, is "crowded".[16, 33, 35] Compass is not the only company developing dual-angiogenesis or dual-checkpoint inhibitors.[22, 31, 37] If a competitor, such as Summit Therapeutics, achieves faster or more robust approval in a shared indication like NSCLC or CRC, Compass’s candidate (CTX-10726) might be relegated to a niche or "salvage" therapy role, limiting its peak sales potential.[16, 31] Furthermore, the rapid advancement of other modalities, such as personalized vaccines or cellular therapies, could change the standard of care before Compass’s assets reach the market.[34, 46]

4.3 Regulatory or Legal Risks

Obtaining FDA approval is a non-linear process.[2, 12] Even with positive Phase 2/3 data, the FDA may require an additional confirmatory trial or raised concerns regarding the manufacturing and CMC (Chemistry, Manufacturing, and Controls) section of the BLA.[7, 12] Tovecimig’s use of paclitaxel as a comparator—rather than the NCCN-preferred Folfox—has been a point of criticism among some analysts and could potentially impact the "commercial standard of care" argument during regulatory review.[43]

4.4 Balance Sheet and Capital Allocation Risks

While $209 million is a substantial sum, it is finite.[1, 7] If the tovecimig survival data is ambiguous, necessitating further studies, or if the CTX-8371 expansion trials consume capital faster than anticipated, Compass may be forced to raise capital at a time when its stock price is depressed.[1, 6, 7] This would lead to significant dilution for existing shareholders.[7]

4.5 Macroeconomic Sensitivities

• Drug Pricing Reform: Future revenues in the U.S. could be impacted by the Medicare drug price negotiation provisions of the Inflation Reduction Act.[47] While Orphan Drugs currently have some exemptions, any broadening of these rules could reduce the lifetime value of the company’s pipeline.[12, 47]
• Interest Rate Volatility: As a "long-duration" asset where cash flows are expected years in the future, the valuation of CMPX is highly sensitive to the discount rate.[2, 9] A "higher-for-longer" interest rate environment would likely suppress the valuation of the company regardless of its clinical success.[7, 9]
• Early Warning Signs: Investors should watch for any delay in the April 2026 data reporting, any "refile" or "refusal to file" from the FDA regarding the BLA, or a sudden increase in G&A spending that is not tied to a successful clinical readout.[1, 6, 7, 43]

SURVIVAL DATA BINARY

5. 5-Year Scenario Analysis

The following scenarios model the potential trajectory for Compass Therapeutics through 2031, based on the clinical success and market penetration of its lead assets.[41]

5.1 Base Case Scenario (Probability: 50%)

In the base case, tovecimig (CTX-009) receives FDA approval for second-line biliary tract cancer in early 2027 following positive OS/PFS data in 2026.[1, 12, 18] The company successfully launches the product, capturing a meaningful portion of the 2L BTC market.[21, 24, 34]

• Key Fundamentals: Tovecimig becomes the preferred second-line therapy for BTC in the U.S..[13, 24] CTX-8371 advances into pivotal trials for NSCLC.[16, 28]
• Revenue: Reaches $357 million by year 5 (2031), driven primarily by BTC sales and early-stage licensing milestones for CTX-10726.[41]
• Margins/Earnings: Reaches EBITDA break-even by year 4; year 5 net margin of 18%.[41, 48]
• Share Count: Assumes dilution to 215 million shares to fund commercialization and Phase 3 expansion.[6]
• Valuation Multiple: 8x forward sales multiple, consistent with commercial-stage oncology biotechs with a growing pipeline.[10, 41]
• Implied Share Price: $13.28.

5.2 High Case Scenario (Probability: 25%)

The high case assumes tovecimig demonstrates a "transformational" survival benefit that allows it to displace standard-of-care in both BTC and refractory CRC.[6, 29, 43] Additionally, CTX-10726 shows superior efficacy to ivonescimab in early trials, leading to a multi-billion dollar partnership with a major pharmaceutical firm.[16, 19]

• Key Fundamentals: Tovecimig achieves 40%+ penetration in BTC and 10% in refractory CRC.[22, 29] CTX-8371 receives accelerated approval in Hodgkin Lymphoma.[1, 49]
• Revenue: Year 5 revenue of $950 million.[33, 41]
• Margins/Earnings: Year 5 net margin of 30% due to favorable pricing and high-yield manufacturing.[16, 28]
• Share Count: Controlled at 200 million shares due to partnership cash inflows.[6, 18]
• Valuation Multiple: 12x forward sales, reflecting premium "platform" value and high growth.[10, 42]
• Implied Share Price: $57.00.

5.3 Low Case Scenario (Probability: 25%)

The low case assumes tovecimig fails the OS endpoint in BTC, resulting in the FDA rejecting the BLA or requiring a new, multi-year trial.[43, 45] The company is forced to pivot to its earlier-stage assets, resulting in significant delays and capital destruction.[7, 45]

• Key Fundamentals: Tovecimig BTC program is suspended; focus shifts entirely to early-stage CTX-10726 and CTX-471.[1, 7]
• Revenue: Minimal revenue ($10M - $20M) from non-core segments or minor royalties.[8, 9]
• Margins/Earnings: Significant ongoing losses; company enters a survival/restructuring phase.[1, 7]
• Share Count: Increases to 250 million through "rescue" financing.[6, 7]
• Valuation Multiple: 2x sales (or 0.8x cash value).[7, 10]
• Implied Share Price: $1.25.

5.4 Scenario Summary Table

Scenario	Year 5 Revenue	Margin / Earnings Assumption	Valuation Multiple (P/S)	Implied Share Price	5-Year Total Return (CAGR)	Probability
High Case	$950 Million	30% Net Margin	12.0x	$57.00	+61.2%	0.25
Base Case	$357 Million	18% Net Margin	8.0x	$13.28	+20.1%	0.50
Low Case	$15 Million	Deep Losses	2.0x	$1.25	-26.4%	0.25

Probability Weighted Outcome (Target Price): $21.20

DATA-DRIVEN ASCENT EXPECTED

6. Qualitative Scorecard

Metric	Score (1-10)	Narrative
Management Alignment	7	CEO Thomas Schuetz directly owns 3.28% of the company, valued at over $32 million.[50] Compensation is heavily weighted toward stock and options (81.4%), aligning leadership with long-term share performance.[50] Recent inducement grants for the new CMO and CCO further emphasize this equity-focused model.[51]
Revenue Quality	2	Currently extremely low quality as there is no recurring product revenue.[1, 7] The company is entirely pre-revenue, meaning current "income" is effectively just interest on cash.[7, 8, 9]
Market Position	6	Compass is a leader in the second-line BTC niche, but it is a "fast-follower" or underdog in the broader PD-1/VEGF and CRC markets.[16, 22, 29] The 17.1% ORR in BTC is a strong signal of market-leading potential in that specific indication.[13, 14]
Growth Outlook	9	If clinical benchmarks are met, the growth trajectory is parabolic, moving from $0 to potentially $1 billion in revenue within a decade.[41, 44] The pipeline is diversified across four distinct programs, providing multiple "shots on goal".[2, 30]
Financial Health	8	Outstanding for a clinical-stage biotech.[1] A $209 million cash balance with a runway into 2028 provides a level of durability and "choke point" protection that many peers lack.[6, 7]
Business Viability	7	The durability of the StitchMabs™ platform suggests a sustainable discovery engine.[23] The main choke point is the survival data readout, which acts as a binary gate for the company's primary asset.[12, 13, 43]
Capital Allocation	8	Management has shown excellent timing in capital markets, raising $129 million during a period of clinical momentum in 2025.[1, 18] Spending is focused heavily on manufacturing for late-stage assets, which is the correct priority for a company nearing BLA filing.[1, 16]
Analyst Sentiment	9	Strong Buy/Moderate Buy consensus across 14-22 analysts.[36, 42, 44, 52] Price targets consistently imply significant upside, suggesting the professional community is broadly optimistic about the upcoming survival data.[42, 44]
Profitability	1	No history of profitability and none expected for several years.[1, 7, 10, 41]
Track Record	6	The company has successfully navigated multiple assets into clinical trials and recently delivered a "hit" on a primary Phase 2/3 endpoint.[13, 30] However, there is no history of bringing a drug to market yet.[2, 12]

BLENDED QUALITATIVE SCORE: 5.9 / 10

HIGH OPTIONALITY PLAY

7. Conclusion & Investment Thesis

The investment thesis for Compass Therapeutics, Inc. (CMPX) is centered on the imminent transformation of the company from a clinical-stage research organization to a commercial-stage oncology innovator.[1, 2, 6] The fundamental value of the company is currently concentrated in its lead asset, tovecimig, which has already cleared the primary hurdle of achieving statistically significant response rates in biliary tract cancer—a difficult-to-treat indication with high unmet need.[12, 13, 14, 24]

The critical catalyst for the next 12 months is the reporting of overall survival (OS) and progression-free survival (PFS) data in April 2026.[6, 8, 43] Should these endpoints mirror the positive trend in ORR and the "lower project mortality" reported by management, Compass will have a clear regulatory path toward a BLA filing and potential commercial launch in 2027.[12, 16, 18, 28] Furthermore, the company’s CTX-10726 (PD-1/VEGF) candidate provides a high-value entry into the multi-billion dollar lung and colorectal cancer markets, with preclinical data suggesting a "best-in-class" profile that could attract significant partnership interest from larger pharmaceutical firms.[16, 19]

Financially, Compass is well-positioned, with a cash runway that extends into 2028, effectively neutralizing the risk of near-term financing pressure during this critical data-rich period.[1, 6, 7] However, investors must remain cognizant of the "binary" nature of biotech readouts; failure to meet survival significance would likely lead to a substantial and rapid repricing of the stock.[43, 45] The company is an attractive candidate for investors seeking exposure to next-generation bispecific antibodies and the lucrative angiogenesis/checkpoint inhibition market, provided they can withstand the inherent volatility of clinical-stage biotechnology.

CLINICAL VALIDATION AWAITED

8. Technical Analysis, Price Action & Short-Term Outlook

As of April 2026, Compass Therapeutics (CMPX) is trading between $5.17 and $5.56, maintaining a position significantly above its 200-day moving average of $4.09, reflecting a long-term bullish trend since the positive ORR data in 2025.[10, 38, 53] Short-term price action has been volatile, with a recent 5% decline on high volume signaling investor anxiety ahead of the pivotal April 2026 survival data readout.[53] The short-term outlook is highly dependent on this news event; if positive, the stock is expected to test its 52-week high of $6.88 and potentially move toward the analyst consensus target of $13.77.[38, 44, 54]

VOLATILITY BEFORE BREAKOUT

---

1. Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update, https://www.nasdaq.com/press-release/compass-therapeutics-reports-2025-financial-results-and-provides-corporate-update
2. Compass Therapeutics Stock (CMPX): Market Outlook and Pipeline Analysis - Bitget, https://www.bitget.com/wiki/compass-therapeutics-stock
3. CMPX Stock Price, News & Analysis | Compass Therapeutics, https://www.stocktitan.net/overview/CMPX/
4. Compass Therapeutics Announces US FDA Clearance of Investigational New Drug Application for a Phase 2 Study of CTX-009, a Bispecific Antibody That Simultaneously Targets Delta-like Ligand 4 (DLL4) and Vascular Endothelial Growth Factor A (VEGF-A), https://investors.compasstherapeutics.com/news-releases/news-release-details/compass-therapeutics-announces-us-fda-clearance-investigational/
5. Compass Therapeutics, https://www.compasstherapeutics.com/
6. Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update, https://investors.compasstherapeutics.com/node/9441/pdf
7. Compass Therapeutics 10-K: $0.0M Revenue, $(0.42) EPS on $(66.5)M Net Loss, https://www.tradingview.com/news/tradingview:1620060708ee8:0-compass-therapeutics-10-k-0-0m-revenue-0-42-eps-on-66-5-m-net-loss/
8. Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update - GlobeNewswire, https://www.globenewswire.com/news-release/2026/03/05/3250042/0/en/Compass-Therapeutics-Reports-2025-Financial-Results-and-Provides-Corporate-Update.html
9. Form 8-K for Compass Therapeutics INC filed 08/12/2024, https://investors.compasstherapeutics.com/static-files/f12c8073-3ec7-40ce-99d5-7c1c9a1dba6c
10. Analysis of Growth Drivers in the Biliary Tract Cancer Market | Intellectia.AI, https://intellectia.ai/news/stock/analysis-of-growth-drivers-in-the-biliary-tract-cancer-market
11. Pipeline - Compass Therapeutics, https://www.compasstherapeutics.com/pipeline/
12. FDA Grants Orphan Drug Designation to Tovecimig for Biliary Tract Cancer | CancerNetwork, https://www.cancernetwork.com/view/fda-grants-orphan-drug-designation-to-tovecimig-for-biliary-tract-cancer
13. Compass Therapeutics (NASDAQ: CMPX) advances bispecific cancer drug pipeline, https://www.stocktitan.net/sec-filings/CMPX/10-k-compass-therapeutics-inc-files-annual-report-3169a784ba99.html
14. Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer - Compass Therapeutics, Inc., https://investors.compasstherapeutics.com/news-releases/news-release-details/tovecimig-ctx-009-meets-primary-endpoint-ongoing-randomized/
15. EdgarFiling - SEC.gov, https://www.sec.gov/Archives/edgar/data/1738021/000117184325005260/exh_992.htm
16. Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update, https://investors.compasstherapeutics.com/news-releases/news-release-details/compass-therapeutics-reports-2025-second-quarter-financial/
17. Form 8-K for Compass Therapeutics INC filed 11/12/2024, https://investors.compasstherapeutics.com/static-files/e17f499e-6c42-4c4e-adc6-661a12eeb416
18. Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update, https://investors.compasstherapeutics.com/news-releases/news-release-details/compass-therapeutics-reports-third-quarter-2025-financial/
19. Compass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting, https://investors.compasstherapeutics.com/news-releases/news-release-details/compass-therapeutics-presents-preclinical-data-ctx-10726/
20. Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing | The Motley Fool, https://www.fool.com/coverage/filings/2026/03/02/investment-advisor-bets-big-on-cmpx-stock-adds-2-5-million-shares-according-to-latest-sec-filing/
21. Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update, https://investors.compasstherapeutics.com/node/9206/pdf
22. Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight - PR Newswire, https://www.prnewswire.com/news-releases/biliary-tract-cancer-market-is-predicted-to-exhibit-remarkable-growth-at-a-cagr-of-10-1-during-the-forecast-period-20252034--delveinsight-302701327.html
23. Platform - Compass Therapeutics, https://www.compasstherapeutics.com/platform/
24. VEGF/DLL4 Bispecific Antibody Meets Primary Endpoint in Phase 2/3 Clinical Trial for Biliary Tract Cancer - Elpiscience, https://www.elpiscience.com/new/vegf-dll4-bispecific-antibody-hits-primary-endpoint-in-phase-2-3-clinical-trial-for-biliary-tract-cancer.html
25. Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical Trial, https://investors.compasstherapeutics.com/news-releases/news-release-details/compass-therapeutics-announces-publication-ctx-8371-preclinical/
26. Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated, https://investors.compasstherapeutics.com/news-releases/news-release-details/compass-therapeutics-receives-fda-fast-track-designation/
27. Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update, https://investors.compasstherapeutics.com/news-releases/news-release-details/compass-therapeutics-reports-2024-financial-results-and-provides/
28. Compass Therapeutics Reports 2025 Second Quarter Financial Results and Provides Corporate Update, https://investors.compasstherapeutics.com/node/9046/pdf
29. Compass Therapeutics Provides Corporate Update, https://investors.compasstherapeutics.com/news-releases/news-release-details/compass-therapeutics-provides-corporate-update-0/
30. Compass Therapeutics Provides Corporate Update and Announces Advancement of a New Drug Candidate, https://investors.compasstherapeutics.com/news-releases/news-release-details/compass-therapeutics-provides-corporate-update-and-announces/
31. Assessing Summit Therapeutics (SMMT) Valuation After Ivonescimab Phase III Data At Major Oncology Conference - Sahm Capital, https://www.sahmcapital.com/news/content/assessing-summit-therapeutics-smmt-valuation-after-ivonescimab-phase-iii-data-at-major-oncology-conference-2026-04-05
32. Biliary Tract Cancer Market Report 2026 - Research and Markets, https://www.researchandmarkets.com/reports/6076187/biliary-tract-cancer-market-report
33. Bile Duct Cancer Market to Grow by $1.07 Billion During 2026-2030 - GlobeNewswire, https://www.globenewswire.com/news-release/2026/03/30/3264424/0/en/Bile-Duct-Cancer-Market-to-Grow-by-1-07-Billion-During-2026-2030-Key-Trends-Investment-Opportunities-and-Competitive-Strategies-Analyzed.html
34. Biliary Tract Cancers Market Size Opportunities, 2025-2032 - CoherentMI, https://www.coherentmi.com/industry-reports/biliary-tract-cancers-btcs-market
35. VEGF Inhibitors for Cancer Market Outlook 2026-2034, https://www.intelmarketresearch.com/vegf-inhibitors-for-cancer-market-36626
36. Compass Therapeutics (CMPX) Stock Forecast and Price Target 2026 - MarketBeat, https://www.marketbeat.com/stocks/NASDAQ/CMPX/forecast/
37. First-line rilvegostomig (rilve) plus chemotherapy (CTx) in advanced biliary tract cancer (BTC): Primary analysis of GEMINI-Hepatobiliary substudy 2 Cohort A. - ASCO, https://www.asco.org/abstracts-presentations/249461
38. Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update, https://www.stocktitan.net/news/CMPX/compass-therapeutics-reports-2025-financial-results-and-provides-lqe6yla863nx.html
39. Compass Therapeutics Sees Major Institutional Investment Boost - Cambridge Today, https://nationaltoday.com/us/ma/cambridge/news/2026/03/14/compass-therapeutics-sees-major-institutional-investment-boost/
40. Compass Therapeutics Inc. (CMPX) Stock AI Rating & Analysis | Danelfin, https://danelfin.com/stock/CMPX
41. CMPX / Compass Therapeutics, Inc. (NasdaqCM) - Forecast, Price Target, Estimates, Predictions - Fintel, https://fintel.io/sfo/us/cmpx
42. Compass Therapeutics Stock Forecast & Predictions: 1Y Price Target $15.50 | Buy or Sell NASDAQ: CMPX 2026 | WallStreetZen, https://www.wallstreetzen.com/stocks/us/nasdaq/cmpx/stock-forecast
43. Compass points the way towards its next readout | ApexOnco - Oncology Pipeline, https://www.oncologypipeline.com/apexonco/compass-points-way-towards-its-next-readout
44. COMPASS THERAPEUTICS INC (CMPX) Forecast, Price Target & Analyst Ratings, https://www.chartmill.com/stock/quote/CMPX/analyst-ratings
45. Compass Therapeutics (CMPX) Stock Forecast: Analyst Ratings, Predictions & Price Target 2026 - Public Investing, https://public.com/stocks/cmpx/forecast-price-target
46. Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate (ADC) - BioSpace, https://www.biospace.com/press-releases/summit-therapeutics-announces-clinical-trial-collaboration-with-gsk-to-evaluate-ivonescimab-in-combination-with-gsks-b7-h3-antibody-drug-conjugate-adc
47. Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update - BioSpace, https://www.biospace.com/press-releases/compass-therapeutics-reports-third-quarter-2025-financial-results-and-provides-corporate-update
48. [DEF 14A] Compass, Inc. Definitive Proxy Statement - Stock Titan, https://www.stocktitan.net/sec-filings/COMP/def-14a-compass-inc-definitive-proxy-statement-763bb04341c4.html
49. Compass Therapeutics Reports 2025 Financial Results and Provides Corporate Update, https://firstwordpharma.com/story/7128233
50. Compass Therapeutics, Inc. (CMPX) Leadership & Management Team Analysis, https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cmpx/compass-therapeutics/management
51. Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), https://investors.compasstherapeutics.com/news-releases/news-release-details/compass-announces-inducement-grants-under-nasdaq-listing-rule/
52. What is the current Price Target and Forecast for Compass Therapeutics, Inc. (CMPX), https://www.zacks.com/stock/research/CMPX/price-target-stock-forecast
53. Compass Therapeutics Stock Price Forecast. Should You Buy CMPX? - StockInvest.us, https://stockinvest.us/stock/CMPX
54. CMPX Implied Volatility Chart Compass Therapeutics - Market Chameleon, https://marketchameleon.com/Overview/CMPX/IV/